Altered expression of imprinted genes in patients with cytogenetically normal‑acute myeloid leukemia: Implications for leukemogenesis and survival outcomes

Yang,Ming-Yu; Hsu,Cheng-Ming; Lin,Pai-Mei; Yang,Chao-Hui; Hu,Ming-Luen; Chen,I-Ya; Lin,Sheng-Fung

doi:10.3892/mco.2023.2690

Altered expression of imprinted genes in patients with cytogenetically normal‑acute myeloid leukemia: Implications for leukemogenesis and survival outcomes

Authors:
- Ming-Yu Yang
- Cheng-Ming Hsu
- Pai-Mei Lin
- Chao-Hui Yang
- Ming-Luen Hu
- I-Ya Chen
- Sheng-Fung Lin
View Affiliations

Affiliations: Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan, R.O.C., Department of Otolaryngology-Head and Neck Surgery, Chiayi Chang Gung Memorial Hospital, Puzi, Chiayi 61363, Taiwan, R.O.C., School of Medicine for International Students and Department of Nursing, I-Shou University, Kaohsiung 82445, Taiwan, R.O.C., Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan 83302, Taiwan, R.O.C., Division of Hematology and Oncology, Department of Internal Medicine, E-Da Hospital, Kaohsiung 82445, Taiwan, R.O.C.
Published online on: October 5, 2023 https://doi.org/10.3892/mco.2023.2690
Article Number: 94
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genomic imprinting, an epigenetic mechanism that regulates gene expression from parental chromosomes, holds substantial relevance in multiple cancers, including hematopoietic malignancies. In the present study, the expression of a panel of 16 human imprinted genes in bone marrow samples from 64 patients newly diagnosed with cytogenetically normal‑acute myeloid leukemia (CN‑AML) were examined alongside peripheral blood samples from 85 healthy subjects. The validated findings of the present study revealed significant upregulation of seven genes [COPI coat complex subunit gamma 2 (COPG2), H19 imprinted maternally expressed transcript (H19), insulin like growth factor 2 (IGF2), PEG3 antisense RNA 1 (PEG3‑AS1), DNA primase subunit 2 (PRIM2), solute carrier family 22 member 3 SLC22A3 and Zinc finger protein 215 (ZNF215)] in patients with CN‑AML (P<0.001). Notably, the expression level of H19 exhibited an inverse association with the survival duration of the patients (P=0.018), establishing it as a predictive marker for two‑ and five‑year survival in patients with CN‑AML. Kaplan‑Meier analysis demonstrated that patients with lower H19 expression had superior two‑ and five‑year survival rates compared with those with higher H19 expression. The results of the present study highlighted the association between loss of imprinting and leukemogenesis in CN‑AML, underscoring the significance of H19 imprinting loss as a prognostic indicator for unfavorable two‑ and five‑year survival in CN‑AML patients.

View Figures

View References

1	Pelcovits A and Niroula R: Acute myeloid leukemia: A review. R I Med J (2013). 103:38–40. 2020.PubMed/NCBI
2	Department of Health Promotion Administration, Ministry of Health and Welfare. Cancer Registry Annual Report, Taiwan, 2016.
3	Wu SJ, Chiang CJ, Lin CT, Tien HF and Lai MS: A nationwide population-based cross-sectional comparison of hematological malignancies incidences between Taiwan and the United States of America. Ann Hematol. 95:165–167. 2016.PubMed/NCBI View Article : Google Scholar
4	Doulatov S, Notta F, Laurenti E and Dick JE: Hematopoiesis: A human perspective. Cell Stem Cell. 10:120–136. 2012.PubMed/NCBI View Article : Google Scholar
5	Marcucci G, Haferlach T and Döhner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol. 29:475–486. 2011.PubMed/NCBI View Article : Google Scholar
6	Čolović N, Denčić-Fekete M, Peruničić M and Jurišić V: Clinical characteristics and treatment outcome of hypocellular acute myeloid leukemia based on WHO classification. Indian J Hematol Blood Transfus. 36:59–63. 2020.PubMed/NCBI View Article : Google Scholar
7	Jurisić V, Pavlović S, Colović N, Djordjevic V, Bunjevacki V, Janković G and Colović M: Single institute study of FLT3 mutation in acute myeloid leukemia with near tetraploidy in Serbia. J Genet. 88:149–152. 2009.PubMed/NCBI View Article : Google Scholar
8	Rowe JM: The increasing genomic complexity of acute myeloid leukemia. Best Pract Res Clin Haematol. 27:209–213. 2014.PubMed/NCBI View Article : Google Scholar
9	Li S, Mason CE and Melnick A: Genetic and epigenetic heterogeneity in acute myeloid leukemia. Curr Opin Genet Dev. 36:100–106. 2016.PubMed/NCBI View Article : Google Scholar
10	Zhang TJ, Zhou JD, Zhang W, Lin J, Ma JC, Wen XM, Yuan Q, Li XX, Xu ZJ and Qian J: H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia. Clin Epigenetics. 10(47)2018.PubMed/NCBI View Article : Google Scholar
11	Wrzeska M and Rejduch B: Genomic imprinting in mammals. J Appl Genet. 45:427–433. 2004.PubMed/NCBI
12	Tucci V, Isles AR, Kelsey G and Ferguson-Smith AC: Erice Imprinting Group. Genomic imprinting and physiological processes in mammals. Cell. 176:952–965. 2019.PubMed/NCBI View Article : Google Scholar
13	Ferguson-Smith AC and Bourc'his D: The discovery and importance of genomic imprinting. Elife. 7(e42368)2018.PubMed/NCBI View Article : Google Scholar
14	Yang MY, Lin PM, Yang CH, Hu ML, Chen IY, Lin SF and Hsu CM: Loss of ZNF215 imprinting is associated with poor five-year survival in patients with cytogenetically abnormal-acute myeloid leukemia. Blood Cells Mol Dis. 90(102577)2021.PubMed/NCBI View Article : Google Scholar
15	Sellers ZP, Bolkun L, Kloczko J, Wojtaszewska ML, Lewandowski K, Moniuszko M, Ratajczak MZ and Schneider G: Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival. Clin Epigenetics. 11(50)2019.PubMed/NCBI View Article : Google Scholar
16	Yu Y, Kou D, Liu B, Huang Y, Li S, Qi Y, Guo Y, Huang T, Qi X and Jia L: LncRNA MEG3 contributes to drug resistance in acute myeloid leukemia by positively regulating ALG9 through sponging miR-155. Int J Lab Hematol. 42:464–472. 2020.PubMed/NCBI View Article : Google Scholar
17	Shaffer LG, McGowan-Jordan J and Schmid M: ISCN 2016: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 2013.
18	Campbell LJ and White JS: Cytogenetic analysis in acute myeloid leukaemia. Methods Mol Biol. 730:63–77. 2011.PubMed/NCBI View Article : Google Scholar
19	Morison IM, Paton CJ and Cleverley SD: The imprinted gene and parent-of-origin effect database. Nucleic Acids Res. 29:275–276. 2001.PubMed/NCBI View Article : Google Scholar
20	Hsu CM, Lin PM, Lin HC, Lai CC, Yang CH, Lin SF and Yang MY: Altered expression of imprinted genes in squamous cell carcinoma of the head and neck. Anticancer Res. 36:2251–2258. 2016.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Walker A and Marcucci G: Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Expert Rev Hematol. 5:547–558. 2012.PubMed/NCBI View Article : Google Scholar
23	Sun H, Pan Y, He B, Deng Q, Li R, Xu Y, Chen J, Gao T, Ying H, Wang F, et al: Gene therapy for human colorectal cancer cell lines with recombinant adenovirus 5 based on loss of the insulin-like growth factor 2 imprinting. Int J Oncol. 46:1759–1767. 2015.PubMed/NCBI View Article : Google Scholar
24	Pan Y, He B, Li T, Zhu C, Zhang L, Wang B, Xu Y, Qu L, Hoffman AR, Wang S and Hu J: Targeted tumor gene therapy based on loss of IGF2 imprinting. Cancer Biol Ther. 10:290–298. 2010.PubMed/NCBI View Article : Google Scholar
25	Zhang Y and Tycko B: Monoallelic expression of the human H19 gene. Nat Genet. 1:40–44. 1992.PubMed/NCBI View Article : Google Scholar
26	Zhao TT and Liu X: LncRNA-H19 inhibits apoptosis of acute myeloid leukemia cells via targeting miR-29a-3p. Eur Rev Med Pharmacol Sci. 23(3 Suppl):224–231. 2019.PubMed/NCBI View Article : Google Scholar
27	Zhao TF, Jia HZ, Zhang ZZ, Zhao XS, Zou YF, Zhang W, Wan J and Chen XF: LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia. Mol Med Rep. 16:3687–3693. 2017.PubMed/NCBI View Article : Google Scholar
28	Hofmann WK, Takeuchi S, Frantzen MA, Hoelzer D and Koeffler HP: Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. Exp Hematol. 30:318–323. 2002.PubMed/NCBI View Article : Google Scholar
29	Mofidi M, Rahgozar S and Pouyanrad S: Increased level of long non coding RNA H19 is correlated with the downregulation of miR-326 and BCL-2 genes in pediatric acute lymphoblastic leukemia, a possible hallmark for leukemogenesis. Mol Biol Rep. 48:1531–1538. 2021.PubMed/NCBI View Article : Google Scholar
30	Asadi M, Gholampour MA, Kompani F and Alizadeh S: Expression of long non-coding RNA H19 in acute lymphoblastic leukemia. Cell J. 25:1–10. 2023.PubMed/NCBI View Article : Google Scholar
31	Zhou JD, Lin J, Zhang TJ, Ma JC, Li XX, Wen XM, Guo H, Xu ZJ, Deng ZQ, Zhang W and Qian J: Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. J Cell Physiol. 233:2444–2450. 2018.PubMed/NCBI View Article : Google Scholar
32	Yang J, Yin Z, Li Y, Liu Y, Huang G, Gu C and Fei J: The identification of long non-coding RNA H19 target and its function in chronic myeloid leukemia. Mol Ther Nucleic Acids. 19:1368–1378. 2020.PubMed/NCBI View Article : Google Scholar
33	Liu FT, Pan H, Xia GF, Qiu C and Zhu ZM: Prognostic and clinicopathological significance of long noncoding RNA H19 overexpression in human solid tumors: Evidence from a meta-analysis. Oncotarget. 7:83177–83186. 2016.PubMed/NCBI View Article : Google Scholar
34	Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, Behroozaghdam M, Entezari M, Salimimoghadam S, Gunduz ES, et al: Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy. Pharmacol Res. 184(106418)2022.PubMed/NCBI View Article : Google Scholar
35	Colovic M, Jurisic V, Pavlovic S, Terzic T and Colovic N: FLT3/D835 mutation and inversion of chromosome 16 in leukemic transformation of myelofibrosis. Eur J Intern Med. 17:434–435. 2006.PubMed/NCBI View Article : Google Scholar
36	Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.PubMed/NCBI View Article : Google Scholar
37	Shen R, Cheng T, Xu C, Yung RC, Bao J, Li X, Yu H, Lu S, Xu H, Wu H, et al: Novel visualized quantitative epigenetic imprinted gene biomarkers diagnose the malignancy of ten cancer types. Clin Epigenetics. 12(71)2020.PubMed/NCBI View Article : Google Scholar